The primary objective of the study was to investigate the effect of food on the pharmacokinetics of MELOXICAM. Cmax, Tmax and AUC of MELOXICAM were defined as the main parameters for the assessmentof bioavailability and bioequivalence of MELOXICAM administered in fasting and fed conditions. The 90% CI for the fed/fasting MELOXICAM did not contained within the acceptance interval (80, 125) and, therefore, it can be concluded that the rate of systemic exposure to MELOXICAM does not fit the claim of bioequivalence between administration in fasting and fed conditions.
No comments:
Post a Comment